Furnley House Foundation FiveAthlon Challenge raises over £11,000 for local Leicestershire charities
Appointment made to head up Midlands expansion of Cornerstone Commercial Finance
Sustainable and inclusive fleet management strategies
Engineering and groundworks contractor fined following HGV driver’s death
Northamptonshire trade counter and drive thru scheme fully let and sold
Trading Standards officials probe retail pricing errors in Derby
What might businesses want from the next government? By James Pinchbeck, partner at Streets Chartered Accountants
Frontier Software support Festival of Work
Boost morale at the East Midlands Bricks Awards 2024
- Most active agent
- Commercial development of the year
- Responsible business of the year
- Residential development of the year
- Developer of the year
- Deal of the year
- Architects of the year
- Excellence in design
- Sustainable development of the year
- Contractor of the year
- Overall winner (this award cannot be entered, with the winner, and recipient of a year of marketing/publicity worth £20,000, selected from those nominated)
Nominations end Thursday 5th September
After winning Architects of the Year at last year’s event, Louise Jones, practice manager at Matthew Montague Architects, said: “We are delighted to win the Architects of the Year Award. 2023 is our 25th year in business and we are thrilled to receive this award in our milestone year. The event was well organised, well attended and thoroughly enjoyable.” Find out who last year’s winners were here.






To be held at:

Top business strategist joins Ashby-based property consultancy
D2N2 LEP incorporated into new East Midlands Combined County Authority
One third of employees feel less engaged at work due to personal finance issues
Nottingham Venues shortlisted for Best Venue at national awards
Two promotions made at East Midlands civil and structural engineering firm
£15.4m aerospace training facility opens in Newark
Dains swoops for NHS VAT specialists
Output growth quickens in the East Midlands, but demand softens in May
Build-to-rent development completes in Nottingham
Derbyshire pharmaceutical company raises £630,000
The net proceeds of the fundraise will be used to advance its three primary work streams whilst also providing working capital into 2025. Specifically:
● Based on the encouraging data obtained on the use of Nuvec for multiple delivery of siRNA and its oral work, the company will commence work with the University of Queensland for the proof of concept for a product to treat irritable bowel disease (IBD). The program will seek to demonstrate through in vitro and in vivo studies that dual loaded Nuvec in an oral capsule can reduce inflammation associated with IBD
● Subject to data from the ongoing work with SRI International Inc (SRI), continue to support further development work with SRI’s MGS technology whilst supporting the co-marketing of any resulting data to collaborators and commercial partners
● The increased funds will provide flexibility to further support Nanogenics in obtaining pre-IND Approval for ECP105 whilst in vivo work concludes and it awaits the result of its application for orphan designation status for ECP105 which, if granted, would potentially give seven years exclusivity in the USA on the product post authorisation
● In addition to the core work streams outlined above, all of which are expected to provide steady newsflow for the rest of the year, work will continue in the background to identify a distribution partner to supply Nuvec to Adeno-Associated virus (AAV) vector companies
● The Board will also look to potentially add additional director(s) with proven track records or contacts in the commercialisation and/or sale of products and IP in the pharmaceutical and biotech space
Nigel Theobald, Chief Executive Officer of the company, said: “We are pleased to have raised these funds in difficult market conditions for small caps. The money will underpin our work efforts whilst we look to move through key milestones and, we believe, value inflexion points, across our three main work streams during the rest of the year.
“In doing so, we hope to be able to co-market our combined technologies with SRI, complete a proof of concept for an oral IBD product and achieve orphan designation and pre IND approval for Nanogenics’ ECP105. All the while this work will be widening and strengthening our IP position across the company.“